UnknownPhase 2NCT03684564
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Studying Antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- Hannah CohenUniversity College London Hospitals NHS Foundation Trust/University College London
- Intervention
- Rivaroxaban(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (6)
- Epsom and St Helier University Hospitals NHS Trust, Epsom, United Kingdom
- Barts and the London Hospitals, Barts Health NHS Trust, London, United Kingdom
- Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
- Kings College Hospital NHS Foundation Trust, London, United Kingdom
- University College Hospitals NHS Foundation Trust, London, United Kingdom
- Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom
Collaborators
University College London Hospitals · Barking, Havering and Redbridge University Hospitals NHS Trust · Hammersmith Hospitals NHS Trust · Epsom and St Helier University Hospitals NHS Trust · Barts & The London NHS Trust · King's College Hospital NHS Trust · Versus Arthritis (Funder)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03684564 on ClinicalTrials.govOther trials for Antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07372170Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS PatientsInfanta Leonor University Hospital
- RECRUITINGNANCT07163338Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)CHU de Reims
- RECRUITINGNANCT06373926Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid SyndromeCentre Hospitalier Universitaire, Amiens
- ENROLLING BY INVITATIONPHASE1NCT06723106Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)Chugai Pharmaceutical
- RECRUITINGNCT06373003Negative Antiphospholipid Syndrome: a Multicentric StudyItalian Society for Rheumatology
- RECRUITINGPHASE1NCT06371417Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Chugai Pharmaceutical
- RECRUITINGPHASE2NCT06747312Effect of Belimumab on Antibody Titers in Primary APS PatientsRuijin Hospital
- RECRUITINGPHASE4NCT05995600Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKESeoul National University Hospital